Overview
- Editors:
-
-
W. B. Harrison
-
Novartis Pharmaceuticals, Australia Pty. Ltd., North Ryde, Australia
-
B. A. C. Dijkmans
-
Academic Hospital, Department of Rheumatology, Vrije Universiteit, Amsterdam, The Netherlands
Access this book
Other ways to access
Table of contents (14 chapters)
-
-
General section
-
-
- W. B. Harrison, B. A. C. Dijkmans
Pages 3-4
-
- N. Fathy, Daniel E. Furst
Pages 5-26
-
-
-
-
-
Disease specific section
-
-
- G. Moroni, O. Della Casa Alberighi, Claudio Ponticelli
Pages 75-89
-
- P. Bacon, David M. Carruthers
Pages 91-108
-
- C. P. Denton, Carol M. Black
Pages 109-129
-
- Niki M. Moutsopoulos, H. M. Moutsopoulos
Pages 131-145
-
- A. M. van Tubergen, Robert B. M. Landewé, Sjef van der Linden
Pages 147-163
-
-
Futurology
-
Front Matter
Pages 185-185
-
- Tom W. J. Huizinga, F. C. Breedveld
Pages 187-192
-
About this book
W. B. Harrison, B. A. C. Dijkmans During the last decade intervention has been instituted for all kinds of disease- even in a premorbid state, as early as possible, to control the activity of the disease, to avoid further damage and to maintain quality of life. Apart from the principle 'Treat now, not later", emphasis is laid on aggressive initial therapy. These adagia have influenced in recent times all fields of medicine, from oncology to infectious diseases and also - the topic of the present edition - the "autoimmune diseases". As an example of the latter, rheumatoid arthritis (RA) demonstrates how the attitude of physicians has been changed. From an expectant point of view in the eighties (primum nil nocere) the attitude has been changed, as we approached and entered the new millennium, to initial ag gressive therapy especially in patients with a poor prognosis. Despite the advance of instituting monotherapy with a single optimised disease-modifying anti-rheumatic drug (DMARD) - with methotrexate as prototype agent in RA - adequate disease re mission is not often achieved, and adverse events may well prevent the use of higher dosages of the single agent in question. Therefore, the next step was to combine two or more DMARDs. The choice of combining DMARDs can be purely practical and based upon the anti-rheumatics most used in daily practice, for instance methotrexate and sulphasalazine. The choice of combining drugs can be influenced by different toxicity patterns to avoid cumulative toxicity.
Editors and Affiliations
-
Novartis Pharmaceuticals, Australia Pty. Ltd., North Ryde, Australia
W. B. Harrison
-
Academic Hospital, Department of Rheumatology, Vrije Universiteit, Amsterdam, The Netherlands
B. A. C. Dijkmans
